10x Genomics, Inc. (NASDAQ:TXG) Shares Sold by Victory Capital Management Inc.

Victory Capital Management Inc. cut its position in shares of 10x Genomics, Inc. (NASDAQ:TXG) by 4.5% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 26,484 shares of the company’s stock after selling 1,241 shares during the quarter. Victory Capital Management Inc.’s holdings in 10x Genomics were worth $1,479,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the company. BlackRock Inc. lifted its stake in 10x Genomics by 14.2% during the first quarter. BlackRock Inc. now owns 9,156,992 shares of the company’s stock worth $696,572,000 after purchasing an additional 1,138,358 shares during the last quarter. Baillie Gifford & Co. lifted its stake in 10x Genomics by 1.8% in the first quarter. Baillie Gifford & Co. now owns 8,753,987 shares of the company’s stock valued at $488,385,000 after buying an additional 151,752 shares during the last quarter. Vanguard Group Inc. lifted its stake in 10x Genomics by 5.7% in the third quarter. Vanguard Group Inc. now owns 8,274,359 shares of the company’s stock valued at $235,654,000 after buying an additional 446,601 shares during the last quarter. FMR LLC lifted its stake in 10x Genomics by 36.5% in the first quarter. FMR LLC now owns 4,372,294 shares of the company’s stock valued at $243,930,000 after buying an additional 1,169,928 shares during the last quarter. Finally, Sands Capital Management LLC lifted its stake in 10x Genomics by 16.6% in the first quarter. Sands Capital Management LLC now owns 3,737,768 shares of the company’s stock valued at $208,530,000 after buying an additional 530,985 shares during the last quarter. 79.16% of the stock is currently owned by institutional investors.

10x Genomics Stock Down 2.4 %

NASDAQ:TXG opened at $36.41 on Friday. The business’s 50-day moving average price is $44.12 and its 200 day moving average price is $51.24. The firm has a market cap of $4.28 billion, a P/E ratio of -24.44 and a beta of 1.82. 10x Genomics, Inc. has a 52-week low of $25.69 and a 52-week high of $63.57.

10x Genomics (NASDAQ:TXG) last released its earnings results on Thursday, August 3rd. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.14). The firm had revenue of $146.82 million for the quarter, compared to analyst estimates of $139.97 million. 10x Genomics had a negative return on equity of 21.69% and a negative net margin of 30.31%. 10x Genomics’s revenue was up 28.1% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.57) earnings per share. Sell-side analysts expect that 10x Genomics, Inc. will post -1.77 EPS for the current year.

Analyst Ratings Changes

A number of research firms have issued reports on TXG. Canaccord Genuity Group reiterated a “buy” rating and issued a $70.00 target price on shares of 10x Genomics in a research note on Tuesday, September 19th. Barclays cut their target price on 10x Genomics from $66.00 to $47.00 and set an “overweight” rating on the stock in a research note on Friday, September 29th. Citigroup raised their target price on 10x Genomics from $65.00 to $75.00 and gave the company a “buy” rating in a research note on Friday, August 4th. Finally, Morgan Stanley restated an “overweight” rating and set a $65.00 price objective on shares of 10x Genomics in a research note on Monday, August 7th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $60.20.

Insider Buying and Selling

In related news, insider Benjamin J. Hindson sold 6,970 shares of 10x Genomics stock in a transaction dated Tuesday, August 1st. The stock was sold at an average price of $62.21, for a total value of $433,603.70. Following the transaction, the insider now owns 284,236 shares of the company’s stock, valued at approximately $17,682,321.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other 10x Genomics news, insider Benjamin J. Hindson sold 6,970 shares of the business’s stock in a transaction dated Tuesday, August 1st. The stock was sold at an average price of $62.21, for a total transaction of $433,603.70. Following the sale, the insider now owns 284,236 shares in the company, valued at approximately $17,682,321.56. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Serge Saxonov sold 2,000 shares of the business’s stock in a transaction dated Thursday, September 14th. The stock was sold at an average price of $49.37, for a total value of $98,740.00. Following the sale, the chief executive officer now owns 862,093 shares in the company, valued at approximately $42,561,531.41. The disclosure for this sale can be found here. Insiders have sold a total of 26,125 shares of company stock valued at $1,326,228 over the last three months. Company insiders own 10.65% of the company’s stock.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products.